Evidence map›Paper›PMID 41225051›Full record

ArticleScientific reports2025

Targeting cancer metabolism through p-cresol mediated Inhibition of pyruvate dehydrogenase kinase 3 in lung cancer.

Akram Ashames, Saleha Anwar, Md Nayab Sulaimani, Pinky, Mohd Shahnawaz Khan, Moyad Shahwan, Suhel Parvez, Md Imtaiyaz Hassan, Khuzin Dinislam, Anas Shamsi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Akram AshamesDepartment of Clinical Sciences, College of Pharmacy and Health Sciences, Ajman University, Ajman, UAE.
Saleha AnwarCentre of Medical and Bio-Allied Health Sciences Research, Ajman University United Arab Emirates, Ajman, UAE.
Md Nayab SulaimaniCenter for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, India.
PinkyDepartment of Toxicology, Jamia Hamdard, New Delhi, India.
Mohd Shahnawaz KhanDepartment of Biochemistry, College of Science, King Saud University, Riyadh, Saudi Arabia.
Moyad ShahwanCentre of Medical and Bio-Allied Health Sciences Research, Ajman University United Arab Emirates, Ajman, UAE.
Suhel ParvezDepartment of Toxicology, Jamia Hamdard, New Delhi, India.
Md Imtaiyaz HassanCenter for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, India.
Khuzin DinislamState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmacology, College of Pharmacy, Department of Cardiology, the Second Affiliated Hospital, Harbin Medical University, 150081, Harbin, China.
Anas ShamsiCentre of Medical and Bio-Allied Health Sciences Research, Ajman University United Arab Emirates, Ajman, UAE. anas.shamsi18@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study provides insight into therapy for lung cancer, establishing p-Cresol (p-C) as an inhibitor of Pyruvate Dehydrogenase Kinase 3 (PDK3). PDK3 is critical in cancer metabolism by regulating the pyruvate dehydrogenase complex, shifting cellular energy production towards glycolysis, and promoting tumor growth and survival under hypoxic conditions. In this study, we have used computational and experimental approaches. Molecular docking reveals that p-C occupies PDK3's binding pocket and forms interactions with key residues, especially Asp 287. Molecular dynamic simulation (MD) studies showed that p-C induced minimum alterations in PDK3, suggesting the structural stability of the PDK3-p-C complex. A fluorescence-based binding study demonstrated the binding of p-C to PDK3 with a binding constant of 3.8 × 10

Indexed as

Lung NeoplasmsProtein Kinase InhibitorsPyruvate Dehydrogenase Acetyl-Transferring KinaseAnimalsCell Line, TumorHumansMolecular Docking SimulationMolecular Dynamics SimulationProtein BindingPDK3 protein, humanProtein Kinase InhibitorsPyruvate Dehydrogenase Acetyl-Transferring KinaseCancer therapeuticsCell proliferationKinase inhibitorsMolecular dynamic simulationPyruvate dehydrogenase kinase

Identifiers

PMID41225051
PMCPMC12612088

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.